Skip to content

Navigating the mainstreaming of psychedelics

Beatriz Caiuby Labate, Henrique Fernandes Antunes, Jamie Beachy, Jordan Sloshower, Clancy Cavnar

Journal of Psychedelic Studies January 1, 2025 DOI: 10.1556/2054.2024.00429 via Elsevier

Summary

AI-generated from the abstract

Mainstreaming psychedelics carries tensions, controversies, and risks that require careful assessment. Overemphasis on biomedicalization sidelines social sciences, humanities, and traditional knowledge. Policy challenges, commodification dangers, and ecological burdens from expanded use are examined. The psychotherapeutic approach to care has been neglected. Inclusion, ethics, and reciprocity are needed to avoid recreating the psychedelic movement as another expression of mainstream capitalism. With the FDA's delay in approving MDMA for PTSD and regulatory hurdles in places like Colorado and Oregon, an informed conversation about the future is urgent, avoiding romanticization and addressing contemporary challenges and ethical risks.

Study at a glance

Characteristics Theoretical or philosophical paper Peer reviewed
Citations 6
Key finding Mainstreaming psychedelics involves significant risks—including biomedicalization, commodification, ecological burdens, and neglect of traditional knowledge—that require inclusion, ethics, and reciprocity to avoid replicating capitalist inequalities.

Abstract

Abstract This article critically addresses one of the most pressing questions of the current moment of the psychedelic wave: Is mainstreaming psychedelics a good thing? Our aim is not to provide a simple “yes” or “no” as an answer but to explore the tensions, controversies, disparities, inequalities, and risks that have risen in the last decades. We discuss the limits of psychedelic science as the paradigm leading this movement and the risks of an overemphasis on biomedicalization to the detriment of the social sciences, humanities, and traditional knowledge. We also examine policy considerations, the dangers of commodification, and the ecological burdens that the expansion of the use of psychedelics is causing. Additionally, the article reflects on the tendency to prioritize the psychotherapeutic approach to care, a topic that has been neglected in the field. The authors put forward the need for inclusion, ethics, and reciprocity to balance the inequalities that risk recreating the psychedelic movement as another expression of mainstream capitalist endeavors. Given the Food and Drug Administration's delay in approval of MDMA for PTSD and the hurdles for regulating access to psychedelics in ceremonial and therapeutic contexts, such as Colorado and Oregon, there is an urgent need to engage in an informed conversation about the future of the psychedelic movement. It is important to avoid the tendency to romanticize this landscape and to do a proper assessment of the contemporary challenges and ethical risks that we face in the future.

Comments

No comments yet.

Log in to comment